The researchers noted that semaglutide might represent a multiple-domain intervention with a single component, explaining that traditional prevention strategies targeting multiple dementia risk factors have shown only modest and inconsistent results
Specific antidote treatments may need to be given before the catheter is removed
The drug is being developed by Eli Lilly and Company, the same pharmaceutical manufacturer behind tirzepatide (Mounjaro), which has received MHRA approval in the UK for type 2 diabetes and, more recently, for weight management
Why We Picked Them: Joseph Clark, DO leads the clinical team
doi: 10.26355/eurrev_201909_19024 59 MangiolaF.IaniroG.FranceschiF.FagiuoliS.GasbarriniG.GasbarriniA
Nov 06, 2023, 19:00 ET The ultra-small 1cm patch, which only needs to be applied once a week, dramatically increases user convenience Daewoong Therapeutics employs the 'CLOPAM' platform to develop 'advanced formulations,' with plans for commercialization by 2028 CEO Seung-Ho Jeon states, "By developing the GLP-1 analogue patch-type formulation, we aim to meet the unmet needs of patients and medical professionals." SEOUL, South Korea, Nov